Company Encyclopedia
View More
name
Akoya Biosciences
AKYA.US
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.
768.31 B
AKYA.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking0/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-354.27%E
    • Profit Margin-59.45%E
    • Gross Margin59.32%A
  • Growth ScoreD
    • Revenue YoY-14.55%E
    • Net Profit YoY30.10%B
    • Total Assets YoY-27.21%E
    • Net Assets YoY-118.00%E
  • Cash ScoreD
    • Cash Flow Margin-168.22%D
    • OCF YoY-14.55%E
  • Operating ScoreB
    • Turnover0.6B
  • Debt ScoreE
    • Gearing Ratio105.23%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Quanterix Corporation Announces Executive Terminations at Akoya Biosciences in Cost-Saving Reorganization Plan

    Quanterix Corporation has announced the termination of certain executives at its subsidiary, Akoya Biosciences, as part of a cost-saving reorganization plan. This strategy aims to achieve annual cash savings of approximately $2.8 million, although it will incur expenses of around $3.3 million in 2025 for severance payments. The company warns that actual results may vary and additional charges could arise during the execution of the plan.

    Reuters·
    US
    AKYA
    0.00%
    Reuters·
    US
    AKYA
    0.00%

    Akoya Biosciences Inc. Finalizes Merger with Quanterix, Terminates Key Agreements

    Akoya Biosciences Inc. has completed its merger with Quanterix, converting each share of Akoya’s stock into 0.1461 shares of Quanterix and $0.38 in cash. The merger also involved the termination of several agreements, including the Equity Distribution Agreement with Piper Sandler & Co., and the repayment of obligations under its Credit Agreement with MidCap Financial Trust. This marks a significant milestone in the integration of the two companies.

    Reuters·
    US
    AKYA
    0.00%
    Reuters·
    US
    AKYA
    0.00%

    Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | QTRX Stock News

    Quanterix Corporation has completed its acquisition of Akoya Biosciences, enhancing its capabilities in biomarker detection for neurology, oncology, and immunology. The deal involved issuing approximately 7.8 million shares and paying $20 million in cash. This acquisition is expected to expand Quanterix's market from $1 billion to $5 billion and accelerate profitability by 2026. Key appointments include Scott Mendel and Dr. Myla Lai-Goldman to the Board of Directors. Quanterix reported $163 million in cash post-transaction, positioning it for future growth.

    StockTitan·
    US
    AKYA
    0.00%
    US
    QTRX
    +12.69%
    StockTitan·
    US
    AKYA
    0.00%
    US
    QTRX
    +12.69%

    Akoya Biosciences Inc. Conducted Special Stockholders Meeting

    Akoya Biosciences Inc. held a special stockholders meeting on July 7, 2025, where stockholders approved the merger proposal with Quanterix Corporation and Wellfleet Merger Sub, Inc. The meeting was not adjourned as the merger proposal was successfully approved. This information was published via EDGAR by Akoya Biosciences Inc.

    Reuters·
    US
    AKYA
    0.00%
    US
    QTRX
    +12.69%
    Reuters·
    US
    AKYA
    0.00%
    US
    QTRX
    +12.69%

    18:18 ET AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

    Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of Akoya Biosciences, Inc. (AKYA) to Quanterix Corporation (QTRX). Shareholders of Akoya would receive 0.318 shares of Quanterix for each Akoya share owned. The investigation aims to assess the adequacy of this consideration and the process leading to it, as there are concerns that it may undervalue the company. Interested parties can contact KSF for more information.

    prnewswire·
    US
    AKYA
    0.00%
    prnewswire·
    US
    AKYA
    0.00%